Lindsay Webb, PhD
Immunologist and cancer biologist passionate about driving innovative research to improve patient health
Research Expertise
About
Publications
203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Ding, J., Webb, L., Patterson, T., Fleury, M., Zieba, A., Horton, H., Hofmeister, R., Gutierrez, D., & Tighe, R. (2021). 203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A214–A214. https://doi.org/10.1136/jitc-2021-sitc2021.203
173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Fleury, M., McCarthy, D., Horton, H., Anderson, C., Watt, A., Zieba, A., Webb, L., Ding, J., Tighe, R., Hofmeister, R., & Gutierrez, D. (2021). 173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A185–A185. https://doi.org/10.1136/jitc-2021-sitc2021.173
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
Cancer Immunology Research / Dec 13, 2023
Xu, C., Zhou, X., Webb, L., Yalavarthi, S., Zheng, W., Saha, S., Schweickhardt, R., Soloviev, M., Jenkins, M. H., Brandstetter, S., Belousova, N., Alimzhanov, M., Rabinovich, B., Deshpande, A. M., Brewis, N., & Helming, L. (2023). M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation. Cancer Immunology Research, 12(2), 195–213. https://doi.org/10.1158/2326-6066.cir-23-0243
Abstract P077: Composition of CD4 T cell subsets and impact on tumor growth control across mouse syngeneic tumor models
Cancer Immunology Research / Jan 01, 2022
Xu, C., Webb, L., Yalavarthi, S., Bourin, C., & Moisan, J. (2022). Abstract P077: Composition of CD4 T cell subsets and impact on tumor growth control across mouse syngeneic tumor models. Cancer Immunology Research, 10(1_Supplement), P077–P077. https://doi.org/10.1158/2326-6074.tumimm21-p077
757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity
Journal for ImmunoTherapy of Cancer / Nov 01, 2021
Xu, C., Rabinovich, B., Deshpande, A., Zhou, X., Pipp, F. C., Schweickhardt, R., Webb, L., Yalavarthi, S., Bourin, C., Ghatak, P., Safi, B., Wollerton, F., Brewis, N., Munoz-Olaya, J., Belousova, N., Alimzhanov, M., Hubensack, M., Halle, J.-P., Blaukat, A., & Moisan, J. (2021). 757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A792–A792. https://doi.org/10.1136/jitc-2021-sitc2021.757
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis–mediated Th17 responses and autoimmunity
Journal of Clinical Investigation / Feb 24, 2020
Webb, L. M., Sengupta, S., Edell, C., Piedra-Quintero, Z. L., Amici, S. A., Miranda, J. N., Bevins, M., Kennemer, A., Laliotis, G., Tsichlis, P. N., & Guerau-de-Arellano, M. (2020). Protein arginine methyltransferase 5 promotes cholesterol biosynthesis–mediated Th17 responses and autoimmunity. Journal of Clinical Investigation, 130(4), 1683–1698. https://doi.org/10.1172/jci131254
NF-κB/mTOR/MYC Axis Drives PRMT5 Protein Induction After T Cell Activation via Transcriptional and Non-transcriptional Mechanisms
Frontiers in Immunology / Mar 19, 2019
Webb, L. M., Narvaez Miranda, J., Amici, S. A., Sengupta, S., Nagy, G., & Guerau-de-Arellano, M. (2019). NF-κB/mTOR/MYC Axis Drives PRMT5 Protein Induction After T Cell Activation via Transcriptional and Non-transcriptional Mechanisms. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.00524
Emerging Role for Methylation in Multiple Sclerosis: Beyond DNA
Trends in Molecular Medicine / Jun 01, 2017
Webb, L. M., & Guerau-de-Arellano, M. (2017). Emerging Role for Methylation in Multiple Sclerosis: Beyond DNA. Trends in Molecular Medicine, 23(6), 546–562. https://doi.org/10.1016/j.molmed.2017.04.004
PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis
The Journal of Immunology / Feb 15, 2017
Webb, L. M., Amici, S. A., Jablonski, K. A., Savardekar, H., Panfil, A. R., Li, L., Zhou, W., Peine, K., Karkhanis, V., Bachelder, E. M., Ainslie, K. M., Green, P. L., Li, C., Baiocchi, R. A., & Guerau-de-Arellano, M. (2017). PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis. The Journal of Immunology, 198(4), 1439–1451. https://doi.org/10.4049/jimmunol.1601702
Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis
Scientific Reports / Jan 17, 2017
Terrazas, C., de Dios Ruiz-Rosado, J., Amici, S. A., Jablonski, K. A., Martinez-Saucedo, D., Webb, L. M., Cortado, H., Robledo-Avila, F., Oghumu, S., Satoskar, A. R., Rodriguez-Sosa, M., Terrazas, L. I., Guerau-de-Arellano, M., & Partida-Sánchez, S. (2017). Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Scientific Reports, 7(1). https://doi.org/10.1038/srep40814
Novel Markers to Delineate Murine M1 and M2 Macrophages
PLOS ONE / Dec 23, 2015
Jablonski, K. A., Amici, S. A., Webb, L. M., Ruiz-Rosado, J. de D., Popovich, P. G., Partida-Sanchez, S., & Guerau-de-Arellano, M. (2015). Novel Markers to Delineate Murine M1 and M2 Macrophages. PLOS ONE, 10(12), e0145342. https://doi.org/10.1371/journal.pone.0145342
Education
University of Cincinnati
BS, Cell and Molecular Biology / May, 2014
The Ohio State University
Ph.D., Biomedical Sciences/ Immunology / December, 2018
Experience
Dynamic Cell Therapies
Principal Scientist / May, 2023 — Present
TCR2 Therapeutics
Senior Scientist / May, 2021 — May, 2023
EMD Serono
Scientist / June, 2019 — May, 2021
Links & Social Media
Join Lindsay on NotedSource!
Join Now
At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.
For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.
For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.